HCM
TEVA icon

Highbridge Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Highbridge Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-384,269
Closed -$17.7M – 1585
2016
Q3 		$17.7M Buy
+384,269
New +$20M 0.28% 83

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Highbridge Capital Management's TEVA Position: Q4 2016 in Review

Highbridge Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 384,269 shares — an estimated $17.7M sold.

Highbridge Capital Management first reported a position in TEVA in Q3 2016 and held it in 1 quarter. The position peaked at $17.7M in Q3 2016. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • Highbridge Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 384,269 Teva Pharmaceuticals shares in Q4 2016, an estimated $17.7M.
  • Highbridge Capital Management first reported a position in Teva Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Highbridge Capital Management's Teva Pharmaceuticals position peaked at $17.7M in Q3 2016.
  • 739 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.